Praxis Precision Medicines/$PRAX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Praxis Precision Medicines
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
- Ticker
- $PRAX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 168
- Headquarters
- Boston, United States
- Website
- praxismedicines.com
PRAX Metrics
BasicAdvanced
$9.1B
-
-$12.76
2.84
-
Price and volume
Market cap
$9.1B
Beta
2.84
52-week high
$392.70
52-week low
$160.11
Average daily volume
518K
Financial strength
Current ratio
14.53
Quick ratio
14.197
Long term debt to equity
0.001
Total debt to equity
0.001
Profitability
EBITDA (TTM)
-406.589
Management effectiveness
Return on assets (TTM)
-29.76%
Return on equity (TTM)
-44.84%
Valuation
Price to book
7.19
Price to tangible book (TTM)
7.19
Price to free cash flow (TTM)
-28.274
Free cash flow yield (TTM)
-3.54%
Free cash flow per share (TTM)
-11.486
Growth
Earnings per share change (TTM)
-1.28%
3-year earnings per share growth (CAGR)
-22.01%
What the Analysts think about PRAX
Analyst ratings (Buy, Hold, Sell) for Praxis Precision Medicines stock.
Analyst projections of the future price of Praxis Precision Medicines stock.
Bulls say / Bears say
Ulixacaltamide has delivered positive Phase 3 results in essential tremor, and its NDA is under FDA review with a January 2027 decision date. Praxis is already building its sales team, giving it a route to launch quickly if approved. (GlobeNewswire)
Relutrigine showed a 53% placebo-adjusted reduction in seizures at week 16 in its confirmatory trial cohort. If approved, it could be the first treatment for SCN2A and SCN8A developmental epilepsies, where treatment options are limited. (Fierce Biotech, GlobeNewswire)
Praxis had $1.3 billion in cash and investments at the end of September, which management expects to fund operations into 2028. That gives it room to prepare potential launches and advance its pipeline without an immediate need to raise more capital. (GlobeNewswire)
The FDA extended relutrigine’s review by three months after classifying added sensitivity analyses as a major amendment, moving its decision date to 27 December 2026. The extra review time adds uncertainty around a key near-term catalyst. (Praxis Precision Medicines)
Vormatrigine missed the main endpoint in the POWER1 trial, and Praxis paused enrolment in POWER2 while it reassessed the programme. This setback weakens the breadth of the pipeline and leaves the drug’s future benefit less certain. (Reuters)
Commercial preparation is becoming costly: third-quarter general and administrative expenses rose to $42.7 million from $12.6 million a year earlier, while the net loss widened to $94.2 million. Higher spending makes delays or a slow launch more costly to absorb. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 9 Nov 2026.
PRAX Financial Performance
Revenues and expenses
PRAX Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing PRAX
AllUSDEURGBP
Fund name | Fund size | $PRAX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.61% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.61% |
SPDR Russell 2000 US Small Cap€R2US | $4.7B | 0.29% |
SPDR Russell 2000 US Small Cap£R2SC | $4.7B | 0.29% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $2.7B | 0.12% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.